Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Axelson
Anders Axelson, Torslanda SE
| Patent application number | Description | Published |
|---|---|---|
| 20090284067 | VEHICLE OCCUPANT RESTRAINT BELT SYSTEM - A 4-point occupant restraint belt system for a vehicle seat having a seat bottom and a back rest. A one-piece belt is connected to the vehicle at upper and lower attachment points disposed adjacent a first side of the vehicle seat, and a buckle is disposed adjacent an opposite second side of the vehicle seat. A latch is slidingly mounted on the belt and engagable with the buckle to secure the belt around a seat occupant in a three-point configuration. A lifting arm has a lowered position wherein it is beneath the belt and adjacent the latch when the latch is engaged with the buckle, and the lifting arm is movable to a raised position wherein it raises a portion of the belt to a position adjacent the back rest above the buckle, thereby creating a 4 | 11-19-2009 |
Magnus Axelson, Hässelby SE
| Patent application number | Description | Published |
|---|---|---|
| 20080221207 | USE OF SPECIFIC CYKLOLIGNANS - The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound is picropodophyllin. | 09-11-2008 |
| 20090326248 | USE OF SPECIFIC CYKLOLIGNANS - The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin. | 12-31-2009 |
| 20100216728 | NEW USE OF SPECIFIC CYKLOLIGNANS - The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin. | 08-26-2010 |
| 20100227797 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES - There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin, deoxypicropodophyllin and anhydropicropodophyllol. There is also described a method of treatment of an eye disease. | 09-09-2010 |
Magnus Axelson, Hässelby SE
| Patent application number | Description | Published |
|---|---|---|
| 20100227797 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES - There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin, deoxypicropodophyllin and anhydropicropodophyllol. There is also described a method of treatment of an eye disease. | 09-09-2010 |
Magnus Axelson, Jarfalla SE
| Patent application number | Description | Published |
|---|---|---|
| 20110178050 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF A HYPERACTIVE IMMUNE SYSTEM - There is disclosed use of certain picro derivatives of cyclolignans for prophylaxis or treatment of diseases or conditions characterised by a hyperactive immune system. Examples of cyclolignans according to the invention include picropodophyllin, deoxypicropodophyllin, anhydropicropodophyllol or deoxyanhydropicropodophyllol. Formula (I) | 07-21-2011 |
Per Axelson, Stockholm SE
| Patent application number | Description | Published |
|---|---|---|
| 20110264177 | IMPLANTABLE MEDICAL LEAD - An implantable medical lead has at least one electric conductor running along a lead body and electrically interconnecting at least one electrode at the distal portion of the lead with at least one lead terminal at the proximal portion of the lead. The lead also has at least one closed channel running along at least a portion of the lead body. The closed channel contains an extracorporeally detectable detection substance. A rupture to the lead will cause the detection substance to leak out of the channel and outside of the lead body. Lead damage can be confirmed by the absence of or a reduced amount of said detection substance inside the lead. | 10-27-2011 |
Stuart L. Axelson, Succasunna, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090043556 | Method of and system for planning a surgery - A system for virtually planning a size and position of a prosthetic implant for a bone on a patient includes a database containing pre-defined form factor information for a plurality of different implants and a circuit for obtaining surface shape information of the bone. The system further includes a circuit for defining baseline location parameters for an implant location in relation to a virtual representation of the bone based on the surface shape information and a circuit for assessing a fit calculation of each implant in relation to the virtual representation of the bone based on the form factor in formation and a plurality of fit factors at each of a plurality of incremental positions in relation to the bone. Still further, the system includes a circuit for selecting a best fit implant size and position from all of the fit calculations. | 02-12-2009 |